From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

(2012) R. Vij et al.   BLOOD

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

(2012) Roman Hájek et al.   BMC CANCER

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

(2012) Sundar Jagannath et al.   Clinical Lymphoma Myeloma & Leukemia

Construction of a microbial natural product library for chemical biology studies

(2012) Naoki Kato et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Carfilzomib

(2012) Paul L. McCormack   DRUGS

Anticancer Drug Discovery from the Marine Environment

(2012) Candida Nastrucci et al.   Recent Patents on Anti-Cancer Drug Discovery

Chemical Genetics–Based Target Identification in Drug Discovery

(2011) Feng Cong et al.   Annual Review of Pharmacology and Toxicology

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Marine natural products

(2011) John W. Blunt et al.   NATURAL PRODUCT REPORTS